Pedro Antonio Pérez-Mancera
University of Salamanca
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Pedro Antonio Pérez-Mancera.
Nature | 2003
Julien Sage; Abigail Miller; Pedro Antonio Pérez-Mancera; Julianne M. Wysocki; Tyler Jacks
Cancer cells arise from normal cells through the acquisition of a series of mutations in oncogenes and tumour suppressor genes. Mouse models of human cancer often rely on germline alterations that activate or inactivate genes of interest. One limitation of this approach is that germline mutations might have effects other than somatic mutations, owing to developmental compensation. To model sporadic cancers associated with inactivation of the retinoblastoma (RB) tumour suppressor gene in humans, we have produced a conditional allele of the mouse Rb gene. We show here that acute loss of Rb in primary quiescent cells is sufficient for cell cycle entry and has phenotypic consequences different from germline loss of Rb function. This difference is explained in part by functional compensation by the Rb-related gene p107. We also show that acute loss of Rb in senescent cells leads to reversal of the cellular senescence programme. Thus, the use of conditional knockout strategies might refine our understanding of gene function and help to model human cancer more accurately.
Oncogene | 2005
Pedro Antonio Pérez-Mancera; Inés González-Herrero; María Pérez-Caro; Noelia Gutiérrez-Cianca; Teresa Flores; Alfonso Gutierrez-Adan; Belén Pintado; Manuel Sánchez-Martín; Isidro Sánchez-García
The SNAIL-related zinc-finger transcription factor, SLUG (SNAI2), is critical for the normal development of neural crest-derived cells and loss-of-function SLUG mutations have been proven to contribute to piebaldism and Waardenburg syndrome type 2 in a dose-dependent fashion. While aberrant induction of SLUG has been documented in cancer cells, relatively little is known about the consequences of SLUG overexpression in malignancy. To investigate the potential role of SLUG overexpression in development and in cancer, we generated mice carrying a tetracycline-repressible Slug transgene. These mice were morphologically normal at birth, and developed mesenchymal tumours (leukaemia and sarcomas) in almost all cases examined. Suppression of the Slug transgene did not rescue the malignant phenotype. Furthermore, the BCR–ABL oncogene, which induces Slug expression in leukaemic cells, did not induce leukaemia in Slug-deficient mice, implicating Slug in BCR–ABL leukaemogenesis in vivo. Overall, the findings indicate that while Slug overexpression is not sufficient to cause overt morphogenetic defects in mice, they demonstrate a specific and critical role for Slug in the pathogenesis of mesenchymal tumours.
Oncogene | 2000
Jesus Perez-Losada; Manuel Sánchez-Martín; M A Rodríguez-García; Pedro Antonio Pérez-Mancera; Belén Pintado; Teresa Flores; E Battaner; Isidro Sánchez-García
The most common chromosomal translocation in liposarcomas, t(12;16)(q13;p11), creates the FUS/TLS-CHOP fusion gene. We previously developed a mouse model of liposarcoma by expressing FUS-CHOP in murine mesenchymal stem cells. In order to understand how FUS-CHOP can initiate liposarcoma, we have now generated transgenic mice expressing altered forms of the FUS-CHOP protein. Transgenic mice expressing high levels of CHOP, which lacks the FUS domain, do not develop any tumor despite its tumorigenicity in vitro and widespread activity of the EF1α promoter. These animals consistently show the accumulation of a glycoprotein material within the terminally differentiated adipocytes, a characteristic figure of liposarcomas associated with FUS-CHOP. On the contrary, transgenic mice expressing the altered form of FUS-CHOP created by the in frame fusion of the FUS domain to the carboxy end of CHOP (CHOP-FUS) developed liposarcomas. No tumors of other tissues were found in these transgenic mice despite widespread activity of the EF1α promoter. The characteristics of the liposarcomas arising in the CHOP-FUS mice were very similar to those previously observed in our FUS-CHOP transgenic mice indicating that the FUS domain is required not only for transformation but also influences the phenotype of the tumor cells. These results provide evidence that the FUS domain of FUS-CHOP plays a specific and critical role in the pathogenesis of liposarcoma.
Oncogene | 2003
Jesus Perez-Losada; Manuel Sánchez-Martín; María Pérez-Caro; Pedro Antonio Pérez-Mancera; Isidro Sánchez-García
Radiation-induced destruction of the hematopoietic system is the primary cause of death based on the findings that transfer of normal bone marrow cells prevents death from lethal irradiation. The stem cell factor-c-kit signaling pathway (SCF/c-kit) has been previously implicated in the hematopoietic recovery which prevents death from lethal irradiation, but the molecular mechanisms that mediate this biological effect are unknown. Since mutations on SCF, c-kit and Slug genes have a similar phenotype in mice, we examined if Slug could complement the radiosensitivity of kit-deficient mice. In this report, we show that Slug acts as a radioprotection agent as lack of Slug results in increased radiosensitivity. This effect cannot be recovered by activating SCF/c-kit in lethally irradiated Slug-deficient mice, as SCF-treated mice did not demonstrate stimulation of hematopoietic recovery leading to survival of the Slug-deficient mice. We found that we could complement the hematopoietic failure in lethally irradiated c-kit-deficient mice by transducing them with a TAT-Slug protein. We conclude that the zinc-finger transcription factor Slug is absolutely necessary for survival from lethal irradiation and identify Slug as the molecular target that mediates the radioprotection through SCF/c-kit. These results indicate that Slug may be a molecular component conferring radioresistance to cancer cells.
PLOS ONE | 2008
Pedro Antonio Pérez-Mancera; Camino Bermejo-Rodríguez; Manuel Sánchez-Martín; Fernando Abollo-Jiménez; Belén Pintado; Isidro Sánchez-García
Background FUS-DDIT3 is a chimeric protein generated by the most common chromosomal translocation t(12;16)(q13;p11) linked to liposarcomas, which are characterized by the accumulation of early adipocytic precursors. Current studies indicate that FUS-DDIT3- liposarcoma develops from uncommitted progenitors. However, the precise mechanism whereby FUS-DDIT3 contributes to the differentiation arrest remains to be elucidated. Methodology/Principal Findings Here we have characterized the adipocyte regulatory protein network in liposarcomas of FUS-DITT3 transgenic mice and showed that PPARγ2 and C/EBPα expression was altered. Consistent with in vivo data, FUS-DDIT3 MEFs and human liposarcoma cell lines showed a similar downregulation of both PPARγ2 and C/EBPα expression. Complementation studies with PPARγ but not C/EBPα rescued the differentiation block in committed adipocytic precursors expressing FUS-DDIT3. Our results further show that FUS-DDIT3 interferes with the control of initiation of translation by upregulation of the eukaryotic translation initiation factors eIF2 and eIF4E both in FUS-DDIT3 mice and human liposarcomas cell lines, explaining the shift towards the truncated p30 isoform of C/EBPα in liposarcomas. Suppression of the FUS-DDIT3 transgene did rescue this adipocyte differentiation block. Moreover, eIF4E was also strongly upregulated in normal adipose tissue of FUS-DDIT3 transgenic mice, suggesting that overexpression of eIF4E may be a primary event in the initiation of liposarcomas. Reporter assays showed FUS-DDIT3 is involved in the upregulation of eIF4E in liposarcomas and that both domains of the fusion protein are required for affecting eIF4E expression. Conclusions/Significance Taken together, this study provides evidence of the molecular mechanisms involve in the disruption of normal adipocyte differentiation program in liposarcoma harbouring the chimeric gene FUS-DDIT3.
Oncogene | 2002
Pedro Antonio Pérez-Mancera; Jesus Perez-Losada; Manuel Sánchez-Martín; Maria Aranzazu Rodríguez-García; Teresa Flores; Enrique Battaner; Alfonso Gutierrez-Adan; Belén Pintado; Isidro Sánchez-García
Fusion proteins created by chromosomal abnormalities are key components of mesenchymal cancer development. The most common chromosomal translocation in liposarcomas, t(12;16)(q13;p11), creates the FUS–CHOP fusion gene. In the past, we generated FUS–CHOP and CHOP transgenic mice and have shown that while FUS–CHOP transgenic develop liposarcomas, mice expressing CHOP, which lacks the FUS domain, display essentially normal white adipose tissue (WAT) development, suggesting that the FUS domain of FUS–CHOP plays a specific and critical role in the pathogenesis of liposarcoma. To test the significance of FUS and CHOP domain interactions within a living mouse, we generated mice expressing the FUS domain and crossed them with CHOP-transgenic mice to generate double-transgenic FUSxCHOP animals. Here we report that expression of the FUS domain restores liposarcoma development in CHOP-transgenic mice. Our results provide genetic evidence that FUS and CHOP domains function in trans for the mutual restoration of liposarcoma. These results identify a new mechanism of tumor-associated fusion genes and might have impact beyond myxoid liposarcoma.
Current Genomics | 2002
Pedro Antonio Pérez-Mancera; J. Perez-Losada; M. A. Sanchez-Martin; A. Rodriguez-Garcia; R. Jimenez; Isidro Sánchez-García
Research in our laboratory is supported by DGCYT (1FD97-0360, SAF2000-0148, BIO2000-0453-P4-02 and 1FD97-1126), Fundacion Cientifica of the AECC, Junta de Castilla y Leon (C.S.12/99 and C.S.I. 3/01), FIS (99/0935 and 01/0114), and NIH grant (1 R01 CA79955-01). PAPM and ARG are scholarship holders from M.E.C., and CSIC-GLAXO, respectively.
Journal of Biological Chemistry | 2005
Sonia Mulero-Navarro; Eulalia Pozo-Guisado; Pedro Antonio Pérez-Mancera; Alberto Álvarez-Barrientos; Inmaculada Catalina-Fernández; Emilia Hernández-Nieto; Javier Sáenz-Santamaría; Natalia Martínez; José M. Rojas; Isidro Sánchez-García; Pedro Fernandez-Salguero
Human Molecular Genetics | 2005
Pedro Antonio Pérez-Mancera; María Pérez-Caro; Inés González-Herrero; Teresa Flores; Alberto Orfao; A. Garcia de Herreros; Alfonso Gutierrez-Adan; Belén Pintado; Ana Sagrera; Manuel Sánchez-Martín; Isidro Sánchez-García
Genomics | 2006
Camino Bermejo-Rodríguez; María Pérez-Caro; Pedro Antonio Pérez-Mancera; Margarita Sánchez-Beato; Miguel A. Piris; Isidro Sánchez-García